Sunil Healthcare Limited is a premier Indian manufacturer of **Empty Hard Capsule Shells**, distinguished as a pioneer in **Double Lock and Triple Lock technology**. Operating under the established brand name **'Sunloc'**, the company provides high-quality closure mechanisms essential for the pharmaceutical and nutraceutical industries. The company has transitioned from a traditional manufacturer to a diversified player, offering a specialized product portfolio: * **Hard Gelatin Capsules:** The flagship product line, manufactured under stringent **WHO-GMP** norms using **100% natural** materials. * **HPMC (Hydroxypropyl Methylcellulose) Capsules:** Launched in **August 2018**, this segment targets the high-growth vegetarian and premium pharmaceutical markets. * **Pullulan Capsules:** A recent addition catering to the demand for plant-based, organic-compliant, and premium-tier shells. * **Versatile Sizing:** Production capabilities span nine distinct sizes: **00, 0SEL, 0EL, 0, 1, 2, 3, 4, and 5**. --- ### **Manufacturing Excellence and Operational Infrastructure** The company operates a state-of-the-art facility in **Alwar, Rajasthan**, strategically located **163 kms** from Indira Gandhi International Airport to facilitate efficient logistics. **Capacity and Quality Benchmarks:** * **Installed Capacity:** Scaled to **1,500 crore capsules per annum** (up from 1,300 crore in FY 2021-22) to achieve significant **Economies of Scale**. * **Operational Methodologies:** Employs **TPAM, 5S, Jishu Hozen, Six Sigma**, and **Automatic Inspection Machines** to ensure zero-defect manufacturing. * **Global Certifications:** The facility is **USFDA registered** and holds certifications including **WHO-GMP, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 22000:2018, Halal, and Kosher**. * **Digital Integration:** Operations are fully migrated to **SAP** to enhance internal controls and process efficiency. --- ### **Global Footprint and Export Performance** Recognized as a **'Star Export House'** by the Government of India, Sunil Healthcare maintains a robust international presence through its subsidiaries: * **Sunil Healthcare North America LLC:** Wholly owned subsidiary in the USA. * **Sunil Healthcare Mexico SA DE CV:** Subsidiary located in San Luis Potosi, Mexico. **Revenue Distribution by Geography (₹ Lakhs):** | Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Within India** | **6,587.63** | **7,246.83** | **8,446.72** | | **Outside India** | **1,754.48** | **1,772.36** | **2,602.38** | | **Total Revenue** | **8,342.11** | **9,019.19** | **11,049.10** | *Note: Export share increased to **21%** of total revenue in FY 2024-25, up from **19.37%** the previous year.* --- ### **Financial Performance and Capital Structure** While the company faced a top-line contraction of **6.99%** in FY 2024-25, it demonstrated a significant turnaround in operational profitability. **Key Financial Metrics (Consolidated):** * **Revenue from Operations:** **₹83.42 Crore** * **EBITDA:** **₹13.22 Crore** (a substantial **+48.33%** increase YoY) * **Profit After Tax (PAT):** **₹0.205 Crore** * **Gearing Ratio:** **0.51** (as of March 31, 2025) **Debt and Liquidity Profile:** * **Total Debt:** **₹66.15 Crore** (as of March 2024), comprising **₹20.26 Cr** non-current and **₹45.89 Cr** current borrowings. * **Interest Rates:** Bank term loans range from **6.00% to 11.70%**; working capital facilities range from **6.70% to 11.65%**. * **Credit Rating:** Reaffirmed at **CARE BBB-**, though the outlook was revised to **Negative** in June 2024. * **Dividend Policy:** Growth and expansions are currently financed through **internal accruals**, leading to a decision to skip dividends for the year ended March 31, 2025. --- ### **Growth Strategy and Macro-Alignment** Sunil Healthcare is aligning its internal roadmap with India’s national pharmaceutical ambitions, targeting a domestic market projected to reach **US$ 130 Billion by 2030** and **US$ 450 Billion by 2047**. **Strategic Pillars:** * **Modernization:** Replacing legacy equipment with advanced machinery and new **DG sets** to lower power costs. * **R&D and Innovation:** Transitioning toward **Discovery 1.0**, focusing on synergies with institutions like **NIPER** and **ICMR** under the **PRIP Scheme** (₹5,000 crore outlay). * **Incentive Utilization:** Leveraging **PLI Schemes** (₹15,000 crore for pharma) and the **SPI scheme** for technology upgradation. * **Therapeutic Shift:** Monitoring advancements in **Gene Therapy, ADCs, and DNA/RNA vaccines** to align future manufacturing capabilities. --- ### **Risk Management and Mitigation Framework** The company operates under a structured risk framework to navigate macroeconomic and industry-specific challenges. **Risk Mitigation Strategies:** * **Customer Concentration:** No single customer exceeds **35%** of total domestic or export revenue; one major customer currently contributes over **10%**. * **Currency Risk:** Managed via natural hedging, as **~25%** of revenue is derived from exports (USD/Euro). * **Credit Risk:** Utilizes **credit insurance** for domestic clients and **ECGC Ltd.** coverage for exports; standard credit cycles range from **0 to 150 days**. * **Supply Chain:** Actively developing domestic alternatives to reduce dependence on **Chinese imports** for intermediates. **Contingent Liabilities (as of March 31, 2025):** * **EPCG Scheme:** **₹1.24 Crore** (contingent on export obligations). * **Advance License Scheme:** **₹1.87 Crore**. * **Provident Fund Dispute:** **₹2.72 Crore** in disputed interest and penalties. * **Capital Commitments:** **₹13.18 Lakhs** remaining for capital accounts.